Scarica l'app Stockscreener
2.07
1.90%
-0.04
Dopo l'orario di chiusura:
2.10
0.03
+1.45%
In 8 Bio Inc Borsa (INAB) Ultime notizie
Climb Bio Publishes Long-Term Data on Budoprutug - TradingView
PALI back in Nasdaq bid-price compliance; 133.0M shares out - Stock Titan
[8-K] Inmune Bio, Inc. Reports Material Event | INMB SEC FilingForm 8-K - Stock Titan
[8-K] Annovis Bio, Inc. Reports Material Event | ANVS SEC FilingForm 8-K - Stock Titan
[8-K] – Inmune Bio, Inc. (INMB) (CIK 0001711754) - Stock Titan
Inmune Bio Inc Announces Participation in Dermatologic Panel - TradingView
Oct 22 CEO Panel: INmune Bio's CORDStrom for RDEB — David Moss at Maxim Growth Summit in NYC - Stock Titan
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108 - GlobeNewswire
Is Mustang Bio Inc. stock ready for a breakoutJuly 2025 Closing Moves & Free Low Drawdown Momentum Trade Ideas - newser.com
OrbiMed Funds Buy into Adicet Bio Offering; Ownership Diluted to 9.6% - Stock Titan
Layoff Tracker: Ferring To Cut 500 Employees as Part of Business Model Shift - BioSpace
Korro Bio, Inc. (KRRO) Stock Price, News, Quote & History - Yahoo
Palisade Bio, Inc. Cancels Special Meeting of Stockholders - TradingView
[8-K] PALISADE BIO, INC. Reports Material Event | PALI SEC FilingForm 8-K - Stock Titan
[SCHEDULE 13G] PALISADE BIO, INC. SEC Filing - Stock Titan
Perceptive Discloses 9.99% Stake in Palisade Bio (12.24M Shares) - Stock Titan
PALI grants 7,665,800 RSUs to Chief Medical Officer; vesting over 2 years - Stock Titan
PALI Form 4: 9.18M RSUs granted to director/officer - Stock Titan
Bio, semiconductor, content firms to reboot Korea’s IPO market - KED Global
Deep Track discloses 6.43M pre-funded warrants, holds 9.99% of PALI - Stock Titan
Nuvation Bio Inc. (NUVB): A Bull Case Theory - Insider Monkey
PlayStation sale round-up for North America October 8, 2025 - TrueTrophies
Brokerages Set Gossamer Bio, Inc. (NASDAQ:GOSS) Price Target at $8.50 - Defense World
[8-K] Adicet Bio, Inc. Reports Material Event | ACET SEC FilingForm 8-K - Stock Titan
Morning Market Movers: SPRB, LXEO, BMEA, Seeing Big Swings - RTTNews
70.0M shares: Adicet Bio Prices $80M Registered Direct Offering - Stock Titan
Adicet's ADI-001 yields immune-reset signals; Phase 2 targeted Q2 2026 - Stock Titan
Morning Market Movers: DBVT, CLPT, DWTX, Seeing Big Swings - RTTNews
$138M Raised: Palisade Bio Closes Upsized Offering to Fund Phase 2 PALI-2108 - Stock Titan
Biopsy Devices Market Poised for Steady Growth by 2032, Fueled by Innovation and Increasing Surgical Procedures | DelveInsight - The Globe and Mail
Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
Mucopolysaccharidosis III Pipeline 2025: Pioneering Clinical - openPR.com
Wheeler Bio Appoints Jay Benson as Chief Operating Officer - PR Newswire
Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock - Yahoo Finance
Biotech Adicet Bio Issues New Employee Stock Options at $0.81 Under Special Inducement Plan - Stock Titan
Cancer Detection Biotech bioAffinity Technologies Raises $4.8M Through Public Stock Offering at $2.50 - Stock Titan
United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday - Benzinga
180-Patient Phase 3 Trial: Nuvation Bio Tests IBTROZI for Early-Stage Lung Cancer Prevention - Stock Titan
Climb Bio stock price target raised to $8 from $7 at BTIG on CLYM116 potential - Investing.com India
24-Week TSLP Inhibition: Upstream Bio's Verekitug Shows Breakthrough Respiratory Disease Treatment Data - Stock Titan
KALA BIO Announces Topline Results from CHASE Phase 2b - GlobeNewswire
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint - Yahoo Finance
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN - GlobeNewswire
Published on: 2025-09-27 16:04:15 - newser.com
What the charts say about Instil Bio Inc. todayBull Run & Weekly High Potential Stock Alerts - newser.com
What analysts say about INmune Bio Inc stockTechnical Breakout Signals & Free Daily Stock Hotspot Analysis - Early Times
Can Climb Bio Inc. recover in the next quarter2025 Market Overview & AI Enhanced Execution Alerts - newser.com
Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025 - Business Wire
Cabaletta Bio, Inc. $CABA Shares Purchased by Acadian Asset Management LLC - MarketBeat
INmune Bio, Inc. (NASDAQ:INMB) Short Interest Down 29.8% in August - MarketBeat
Co-Diagnostics, Inc. Announces Closing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - BioSpace
Is KALA BIO Inc. stock ready for a breakoutEarnings Recap Report & Long-Term Safe Investment Plans - newser.com
Kalexo enters dyslipidemia fray with preclinical siRNA candidate - BioWorld MedTech
bluebird bio Rebrands as Genetix Biotherapeutics, Returning to Its Foundational Roots - Business Wire
100% Clinical Response: Palisade Bio's Novel UC Drug Shows Promise in Phase 1b with Zero Serious Side Effects - Stock Titan
Can Palisade Bio Inc. recover in the next quarter2025 Momentum Check & Free Fast Entry Momentum Trade Alerts - newser.com
Passage Bio Inc. stock retracement – recovery analysisMarket Risk Report & Safe Entry Momentum Stock Tips - newser.com
Pattern recognition hints at Boundless Bio Inc. upsideJuly 2025 Momentum & Fast Gain Swing Alerts - newser.com
Nuvation Bio: A Rare Gem In The Risky Biotech Space (NYSE:NUVB) - Seeking Alpha
Does Climb Bio Inc. show high probability of reboundJuly 2025 Update & Verified Momentum Stock Watchlist - newser.com
Can GRI Bio Inc. recover in the next quarterGlobal Markets & High Accuracy Buy Signal Tips - newser.com
Will GRI Bio Inc. continue its uptrend2025 Year in Review & Stock Portfolio Risk Control - newser.com
Gossamer Bio, Inc. (NASDAQ:GOSS) Receives $8.50 Average Price Target from Brokerages - Defense World
First-Ever Phase 3 Trial for Stargardt Disease: Belite Bio's Tinlarebant Could Be Breakthrough Treatment - Stock Titan
GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewswire
Gossamer Bio stock upgraded at UBS (GOSS:NASDAQ) - Seeking Alpha
Novartis to acquire Tourmaline Bio for $1.4 billion - Reuters
1.84%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):